🔎 Trials Near Me

首页 › 非小细胞肺癌 › 缅因州

缅因州 的 非小细胞肺癌 临床试验

缅因州 有 16 项针对 非小细胞肺癌 的研究正在招募参与者。

缅因州 的城市

官方研究文本（英文）

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Harold Alfond Center for Cancer Care, Augusta
  • MaineHealth Waldo Hospital, Belfast
  • Lafayette Family Cancer Center-EMMC, Brewer
  • 以及另外 5 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  • MaineHealth Coastal Cancer Treatment Center, Bath
  • MaineHealth Cancer Care and IV Therapy - Brunswick, Brunswick
  • MaineHealth Maine Medical Center - Portland, Portland
  • 以及另外 3 项
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT07293247

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  • New England Cancer Specialists ( Site 0139), Westbrook
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT07190248

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Harold Alfond Center for Cancer Care, Augusta
  • MaineHealth Maine Medical Center- Scarborough, Scarborough
  • MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT06498635

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  • New England Cancer Specialists ( Site 0095), Westbrook
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06312137

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Maine Medical Center, Portland
  • MaineHealth Cancer Care and Blood Disorders Scarborough, Scarborough
  • MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06758401

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  • New England Cancer Specialists ( Site 0143), Westbrook
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06170788

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • New England Cancer Specialists, Westbrook
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT06890598

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  • Research Site, Scarborough
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月18日 · NCT06692738

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  • Research Site, South Portland
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月4日 · NCT07291037

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Lafayette Family Cancer Center-EMMC, Brewer
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年6月3日 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • Lafayette Family Cancer Center-EMMC, Brewer
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年5月6日 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Lafayette Family Cancer Center-EMMC, Brewer
招募中2 期
18 Minutes · 所有性别 · 更新于 2026年5月5日 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Harold Alfond Center for Cancer Care, Augusta
  • MaineHealth Waldo Hospital, Belfast
  • Lafayette Family Cancer Center-EMMC, Brewer
  • 以及另外 5 项
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年5月5日 · NCT06616584

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Harold Alfond Center for Cancer Care, Augusta
  • MaineHealth Waldo Hospital, Belfast
  • MaineHealth Maine Medical Center - Biddeford, Biddeford
  • 以及另外 7 项
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年3月17日 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Scarborough
招募中观察性研究
所有年龄段 · 所有性别 · 更新于 2025年10月28日 · NCT03452774

数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。